ODOBGYNDECODED

← Clinical library

Gynaecology

Polycystic Ovary Syndrome

IN REVIEWv3🇮🇳 India-firstPENDING CLINICAL VERIFICATION
2 of 3 criteria (hyperandrogenism/OV dysfunction/PCOM-or-elevated AMH in adults). Lifestyle foundation. Menstrual control COCP/progestogens; metformin metabolic; LETROZOLE first-line ovulation induction (2023 guideline, high certainty).

Admission & discharge ↓

Reviewer note: Medication regimens and dependent emergency instructions checked 17 October 2026. These targeted checks do not certify every statement in the module. Admission/discharge guidance checked 18 October 2026. This adds a scoped clinical synthesis and does not certify every statement in the module.

Clinical detail

Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.

PCOS assessment extends beyond ovarian appearance. The 2023 international guideline links reproductive symptoms to metabolic and psychological health and recommends management based on the patient’s goals.

Assessment & interpretation

  • In adults, use the diagnostic algorithm and exclude alternative causes. Irregular cycles with hyperandrogenism do not require ultrasound or AMH to establish the diagnosis.
  • AMH can support assessment of polycystic ovarian morphology in adults but is not a standalone diagnostic test and should not be used for diagnosis in adolescents.
  • Assess blood pressure, lipids and glycaemic status, and ask about depression, anxiety and sleep-related symptoms.

Decisions that change management

  • Match care to cycle regulation, endometrial protection, metabolic health or fertility priorities. Lifestyle support is relevant across body sizes.
  • Letrozole is the guideline’s preferred first-line ovulation-induction medicine for anovulatory infertility when no other infertility factor is present; this requires an assessed, monitored fertility pathway.

Follow-up & safety-netting

  • Reassess glycaemic status according to individual risk. A 75-g OGTT is the most accurate glycaemic test in this population.
  • Explain that endometrial cancer risk is increased, but routine screening of asymptomatic patients is not recommended; persistent abnormal bleeding needs evaluation.
Sources for this detail:
International PCOS Guideline Network · 2023checked

Admission & discharge

Care setting: Usually outpatient; admission is for an acute complication, not PCOS itself

Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.

When admission or continued hospital care is needed

  • Severe bleeding/instability, acute pelvic pain suggesting another diagnosis, or complications of fertility treatment requires urgent assessment; OHSS follows the fertility-complication pathway.

When clinic, day care or home care may be suitable

  • PCOS assessment, cycle/endometrial protection, metabolic care and fertility treatment are normally outpatient services.

Before going home

  • Any acute presentation has been assessed, a specific symptom/goal-based treatment is agreed and follow-up is feasible.

Discharge medicines and treatment changes

  • State why each medicine is prescribed: cycle/endometrial protection, metabolic care or monitored ovulation induction are different indications. Do not start ovulation-induction medicines without the required monitoring/service plan.

Tests, pending results and their reviewer

  • Document indicated metabolic/endocrine tests, bleeding/endometrial assessment and the person responsible for results.

Home care and counselling

  • Discuss cycle tracking, when prolonged amenorrhoea/abnormal bleeding needs review, lifestyle support, pregnancy goals and contraception if pregnancy is not wanted.

Follow-up: when and what to review

WhenAction / responsible service
At the planned PCOS/metabolic review
Review cycles, medicine tolerance, cardiometabolic risk and endometrial protection.
During fertility treatment
Use the monitored-cycle appointments and emergency contact arrangements.

Return urgently

  • Acute severe pelvic pain, heavy bleeding, faintness or breathlessness/abdominal swelling during fertility treatment requires urgent care.

Open the complete discharge checklist →

Sources for this plan:
International PCOS Guideline Network · 2023checkedRCOG · 2016 patient information on current RCOG webpagesummary checked

Treatment

① Immediate stabilization — first minutes

Not acute.

③ First-line treatment & drug regimens
Letrozole — monitored ovulation inductionGloucestershire Hospitals NHS Foundation Trustchecked
Dose2.5 mg daily on cycle days 2–6
RouteOral
FrequencyOnce daily for 5 consecutive days per prescribed cycle
DurationInitial monitored cycle, with review of ovulation/response before changing dose or repeating a course
PreparationOne 2.5 mg tablet daily; day 1 is the first day of fresh menstrual bleeding. Exclude pregnancy before another cycle if no period
Max dose2.5 mg/day in this named NHS starting regimen; dose escalation requires a new fertility prescription, not automatic self-escalation
  • Anovulatory PCOS infertility after assessment of pregnancy, tubal/semen factors and counselling about off-label use
  • PCOS 2023 guidance supports letrozole first line for anovulatory infertility without other infertility factors. Cycle-day schedules vary by clinic; follow one complete prescribed schedule.
Monitoring
  • Ovulation assessment, cycle/pregnancy outcome and ultrasound monitoring where indicated; discuss multiple-pregnancy risk
Contraindications: Possible/existing pregnancy, breastfeeding; hepatic impairment needs specialist assessment
Metformin — PCOS metabolic treatmentInternational PCOS Guideline Network · 2023checked
DoseStart 500 mg/day with food; increase by 500 mg every 1–2 weeks if tolerated toward the individually required dose
RouteOral
FrequencyOnce daily initially, then divided with meals; extended-release requires its own product instructions
DurationContinue while metabolic benefit outweighs adverse effects; review the indication when pregnancy occurs
PreparationUse 500 mg immediate-release tablets for this example; slow titration reduces GI effects
Max doseSuggested PCOS guideline maximum 2.5 g/day in adults and 2 g/day in adolescents, subject to the lower licensed product/renal limit
  • Metabolic features of PCOS, particularly adults with BMI ≥25; not an interchangeable GDM regimen
  • Lifestyle treatment remains foundational. Letrozole is the separate first-line ovulation-induction option.
Monitoring
  • Metabolic response, renal function, GI tolerance and B12 if risk factors/long-term therapy
Contraindications: eGFR <30, metabolic acidosis, hypoxia or major dehydration; withhold during serious acute illness
Ethinylestradiol/levonorgestrel — combined pillMSFchecked
DoseOne active tablet containing ethinylestradiol 30 micrograms +levonorgestrel 150 micrograms daily for 21 days, followed by the 7 inactive tablets in the cited 28-day pack
RouteOral
FrequencyOne tablet at the same time daily, including inactive tablets; start the next pack immediately after day 28
DurationOngoing while eligible, with periodic BP/risk review; stop and assess new contraindications
PreparationCheck the pack has 21 active +7 inactive tablets of the stated formulation. Other pill formulations and extended regimens need their own schedule
Max doseOne scheduled tablet/day; missed-pill/vomiting instructions are a separate decision pathway, not a reason for indefinite extra dosing
  • Eligible nonpregnant patient seeking contraception or PCOS cycle control after BP/VTE/migraine assessment
  • If starting >5 days after menstrual bleeding begins, use backup for 7 days. This formulation is an example; PCOS guidance does not establish one universally preferred progestogen.
Monitoring
  • BP, adherence, bleeding, new migraine aura or VTE symptoms; review interacting medicines
Contraindications: Migraine with aura, active/prior VTE or major thrombotic risk, uncontrolled hypertension, smoking ≥35 years, current breast cancer or severe liver disease; postpartum eligibility is time/breastfeeding dependent
  • Clomiphene 50-100 mg days 2-6 second-line order
  • Gonadotrophins low-dose step-up OR laparoscopic ovarian drilling as second line
Definitive treatment
  • IVF after failed lines; antagonist protocol + agonist trigger/all-freeze for OHSS-risk reduction
Monitoring
  • Follicular tracking during OI (multiple-pregnancy prevention)
  • Annual metabolic review
Response assessment
  • Monofollicular ovulation; regular bleeds on therapy
Treatment failure
  • Clomiphene resistance -> gonadotrophins/LOD; weight programme intensified
Second-line treatment
  • Per guideline hierarchy above
Rescue treatment

OHSS management within infertility module.

⑮ Complications & their management
Endometrial hyperplasia risk

Progestogen withdrawals/LNG-IUS protection; biopsy if prolonged amenorrhoea + risk

Gestational diabetes

Early OGTT when pregnant

Post-treatment care
  • Lifelong weight/mood/metabolic plan

Diagnosis & assessment

Red flags:
  • Haemodynamic instability / severe anaemia -> acute pathway

Initial assessment

  1. Exclude mimics: thyroid, hyperprolactinaemia, NC-CAH, Cushing, androgen tumours
  2. Metabolic panel: OGTT/HbA1c, lipids, BP, sleep-apnoea screen
  3. Psychological screening (guideline-emphasised)

Investigations

TestLooking for
AMH OR TVS follicle count
PCOM criterion (adults)
OGTT/lipids
Metabolic staging

Principles & follow-up

Management principles

Sources (10)

Monash/ESHRE/ASRM/international societies — 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
2023 (Eur J Endocrinol 189(2):G43–G64) · checked 2026-08-23 · verified-live
Open source ↗

Guideline recommendation extracts: letrozole first-line pharmacological ovulation induction (off-label caveat); clomiphene > metformin alone; gonadotrophins second line low-dose step-up; laparoscopic ovarian surgery alternative second line; IVF after failed 1st/2nd line with antagonist protocol + ag…

International PCOS Guideline Network — Recommendations from the 2023 international evidence-based PCOS guideline
· checked 2026-10-18 · verified-live
Open source ↗

Scope: additional clinical-detail explanation for pcos. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Medication check 17 October 2026: metaboli…

Gloucestershire Hospitals NHS Foundation Trust — Ovulation induction with oral agents — patient pathway
· checked 2026-10-17 · verified-live
Open source ↗

Initial letrozole 2.5 mg daily cycle days 2–6 for five days; day-one definition, pregnancy test if no period, response monitoring and reassessment. This named starting pathway does not establish a universal maximum for escalation.

MSF — Ethinylestradiol / levonorgestrel oral
· checked 2026-10-17 · verified-live
Open source ↗

21 active 30-microgram/150-microgram tablets plus 7 inactive in a 28-day pack; one tablet daily, no gap between packs, seven-day backup for a later start and eligibility contraindications. No claim to update every missed-pill algorithm.

RCOG — Ovarian hyperstimulation syndrome — patient information
· checked 2026-10-18 · verified-summary
Open source ↗

Primary information read: mild OHSS may be managed at home; uncontrolled pain/vomiting, failure to improve or inability to attend monitoring can require admission; urine/fluid/renal/thrombosis assessment and avoiding NSAIDs. Edition is 2016, not a newly issued 2026 guideline; no universal anticoagul…

NICE — Postnatal care — NG194
· checked 2026-10-18 · verified-live
Open source ↗

Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.

India MoHFW / NHM — District Hospital Standard Operating Procedures — LaQshya
· checked 2026-10-18 · verified-live
Open source ↗

Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.

WHO — WHO recommendations on quality postnatal care — official recommendation summary
· checked 2026-10-18 · verified-live
Open source ↗

Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.

RCOG — Laparoscopy — recovering well
· checked 2026-10-18 · verified-live
Open source ↗

Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…

NICE — Acutely ill adults in hospital — CG50
· checked 2026-10-18 · verified-live
Open source ↗

Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.